secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-10-05T20:16:48+00:00
Accession:  0001140361-26-038624
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Standard BioTools to sell Microfluidics business to ARCHIMED; close expected in ~30 days
--------------------------------------------------------------------------------

- Standard BioTools (NASDAQ: LAB) signed a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm; closing expected in approximately 30 days.
- No purchase price, revenue multiple, or other financial terms for the Microfluidics sale were disclosed in the press release.
- CEO Michael Egholm called it 'a strong outcome for our employees and our customers' and 'another important step in the strategic actions we laid out' for shareholders.
- Microfluidics will keep operating as part of Standard BioTools until closing; the deal is subject to customary closing conditions.
- Separately pending: a merger with Treeline Biosciences (Form S-4 preliminary proxy filed July 20, 2026) and a sale of the Mass Cytometry unit to Element Biosystems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000114036126038624/0001140361-26-038624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000114036126038624/ef20083295_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-038624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer